Analyst Vikram Purohit of Morgan Stanley maintained a Buy rating on COMPASS Pathways (CMPS – Research Report), with a price target of ...

Patients with non-seasonal depression who were treated with bright light therapy reported a 40% remission rate, according to a recent study.

Bipolar disorder is a long-term mood disorder characterized by major fluctuations in mood — both high and low — that can ...

Supernus (SUPN) announced data in a poster presentation at Psych Congress 2024 with new data from its exploratory open-label Phase 2a clinical ...

The company is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT ... IW is uniquely ...

Q3 2024 Earnings Call Transcript October 30, 2024 Neurocrine Biosciences, Inc. misses on earnings expectations. Reported EPS ...

In a recent ruling, Cora Vides, a 21-year-old woman from Santa Barbara, has been sentenced to six months in a state ...

Sage and its collaborator, Biogen, are focused on the goal of establishing ZURZUVAE as the first line therapy and standard of care for women with postpartum depression (PPD). As of the third quarter ...

Overall, I’m thoroughly impressed with just how well my $20 smart scale held its own against an $8,500 body composition ...

The best investment for you depends on your risk tolerance, timeline and other factors. Many, or all, of the products featured on this page are from our advertising partners who compensate us when ...

agonist being developed as a potential adjunctive treatment for people with major depressive disorder and bipolar disorder ...

Mirtazapine is an FDA- approved, prescription-only medication for major depressive disorder in adults. The medication works by increasing certain hormones in the brain to improve mood. Whichever ...